Sarepta Therapeutics, Inc. $SRPT Shares Acquired by Profund Advisors LLC

Profund Advisors LLC increased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 96.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 76,224 shares of the biotechnology company’s stock after buying an additional 37,350 shares during the period. Profund Advisors LLC owned about 0.07% of Sarepta Therapeutics worth $1,640,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. iSAM Funds UK Ltd purchased a new position in Sarepta Therapeutics in the third quarter worth approximately $25,000. Ancora Advisors LLC increased its position in shares of Sarepta Therapeutics by 200.0% in the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,000 shares during the last quarter. Allworth Financial LP raised its holdings in shares of Sarepta Therapeutics by 2,098.8% in the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 1,721 shares in the last quarter. Parallel Advisors LLC raised its holdings in shares of Sarepta Therapeutics by 165.3% in the 3rd quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 1,256 shares in the last quarter. Finally, Atlantic Union Bankshares Corp purchased a new stake in shares of Sarepta Therapeutics during the 3rd quarter worth $48,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Royal Bank Of Canada boosted their target price on shares of Sarepta Therapeutics from $18.00 to $19.00 and gave the stock a “sector perform” rating in a research note on Tuesday, April 7th. Wall Street Zen raised Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Wells Fargo & Company lowered their price objective on Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating for the company in a research report on Friday, February 27th. Weiss Ratings upgraded Sarepta Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, May 8th. Finally, Wedbush raised their target price on Sarepta Therapeutics from $29.00 to $35.00 and gave the stock an “outperform” rating in a research report on Thursday, March 26th. Nine equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have assigned a Sell rating to the company. According to MarketBeat.com, Sarepta Therapeutics currently has an average rating of “Hold” and a consensus price target of $27.71.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $17.02, for a total transaction of $123,207.78. Following the transaction, the director owned 1,765 shares of the company’s stock, valued at $30,040.30. The trade was a 80.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 6.90% of the stock is owned by corporate insiders.

Sarepta Therapeutics Price Performance

Shares of SRPT opened at $17.12 on Thursday. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.63 and a quick ratio of 2.62. Sarepta Therapeutics, Inc. has a 1-year low of $10.41 and a 1-year high of $44.14. The stock has a market cap of $1.81 billion, a PE ratio of -17.83, a price-to-earnings-growth ratio of 0.19 and a beta of 0.26. The firm has a fifty day moving average price of $20.02 and a 200 day moving average price of $20.00.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $2.18. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The company had revenue of $730.80 million for the quarter, compared to analyst estimates of $474.16 million. During the same quarter last year, the company posted ($3.42) earnings per share. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Sarepta Therapeutics, Inc. will post 3.69 EPS for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.